報價延遲最少15分鐘:2025/01/21 05:40 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
342.41 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-28.08/12.47
|
|
企業價值
11.01B
|
| 資產負債 |
|
每股賬面淨值
267.45
|
| 現金流量 |
|
現金流量率
0.04
|
| 損益表 |
|
收益
2.67B
|
|
每股收益
97.17
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 05:40 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |